MTE #8 The Role of Hepatorenal Syndrome–Acute Kidney Injury Treatment in Acute-on-Chronic Liver Failure Patients Under Consideration for Transplant (Ticketed)

Nov 08 2025
Convention Center: Room 140A, Level 1
12:45 PM - 1:30 PM
Ticketed Event

World Class Speakers

Pratima Sharma, MD, MS
Discussion Leader

Pratima Sharma, MD, MS

University of Michigan Medical Center
Hugo E. Vargas, MD, FAASLD
Discussion Leader

Hugo E. Vargas, MD, FAASLD

Mayo Clinic Arizona

Description

Experts lead participants in a discussion of the complexities, risks, and benefits of treating hepatorenal syndrome-acute kidney injury (HRS-AKI) in patients with acute-on-chronic liver failure being considered for liver transplantation. Topics include treatment strategies, implications for waitlist prioritization, and use of terlipressin.

Journey Maps

Objectives

  • Evaluate various treatment strategies for hepatorenal syndromeacute kidney injury (HRS-AKI).
  • Describe the implications of HRS-AKI treatment on liver transplant waitlist prioritization.
  • Assess the use of terlipressin in patients with acute-on-chronic liver failure listed for liver transplantation.